Reducing harm from injecting pharmaceutical tablet or capsule material by injecting drug users

Drug and Alcohol Review

Volumn 30, Issue 3, 2011, Pages 287-290

  Roux, Perrine ^a,b,c   Carrieri, M Patrizia ^a,b,c   Keijzer, Lenneke ^d   Dasgupta, Nabarun ^e  

^a INSERM   (France)

^b AIX MARSEILLE UNIVERSITY   (France)

^c OBSERVATOIRE RÉGIONAL DE LA SANTÉ PROVENCE ALPES CÔTE D AZUR   (France)

^d Study Lead at Apothicom   (France)

^e University of North Carolina at Chapel Hill   (United States)

Author keywords

Buprenorphine; Filler; Filter; Methylphenidate; Talcosis

Indexed keywords

BUPRENORPHINE; METHYLPHENIDATE;

ARTICLE; CHEMISTRY; COMPARATIVE STUDY; FRANCE; HARM REDUCTION; HUMAN; METHODOLOGY; MICROCAPSULE; PARTICLE SIZE; STANDARD; SUBSTANCE ABUSE; TABLET;

BUPRENORPHINE; CAPSULES; CHEMISTRY, PHARMACEUTICAL; FRANCE; HARM REDUCTION; HUMANS; METHYLPHENIDATE; PARTICLE SIZE; SUBSTANCE ABUSE, INTRAVENOUS; TABLETS;

EID: 79955616367     PISSN: 09595236     EISSN: 14653362     Source Type: Journal    
DOI: 10.1111/j.1465-3362.2011.00285.x     Document Type: Article

References (33)

1. [1] Des Jarlais DC, Arasteh K, Perlis T, etal. Convergence of HIV seroprevalence among injecting and non-injecting drug users in New York City. AIDS 2007;21:231-5.
2. [2] Emmanuelli J, Desenclos JC. Harm reduction interventions, behaviours and associated health outcomes in France, 1996-2003. Addiction 2005;100:1690-700.
3. [3] Bassetti S, Battegay M. Staphylococcus aureus infections in injection drug users: risk factors and prevention strategies. Infection 2004;32:163-9.
4. [4] Ditzen A, Ehricht R, Monecke S. Disseminated cutaneous and pulmonary abscesses in an injecting drug user caused by a Panton-Valentine leucocidin-positive, methicillin-susceptible Staphylococcus aureus strain. Eur J Clin Microbiol Infect Dis 2008;27:1013-15.
5. [5] Hind CR. Pulmonary complications of intravenous drug misuse. 1. Epidemiology and non-infective complications. Thorax 1990;45:891-8.
6. [6] Glatt MM. The changing British drug scene. Lancet 1969;2:429-30.
7. [7] Showalter CV. T's and blues. Abuse of pentazocine and tripelennamine. JAMA 1980;244:1224-5.
8. [8] Rosenblum A, Parrino M, Schnoll SH, etal. Prescription opioid abuse among enrollees into methadone maintenance treatment. Drug Alcohol Depend 2007;90:64-71.
9. [9] Del Giudice P. Cutaneous complications of intravenous drug abuse. Br J Dermatol 2004;150:1-10.
10. [10] Pare JP, Cote G, Fraser RS. Long-term follow-up of drug abusers with intravenous talcosis. Am Rev Respir Dis 1989;139:233-41.
11. [11] Butch AJ, Yokel RA, Sigell LT, Hanenson IB, Nelson ED. Abuse and pulmonary complications of injecting pentazocine and tripelennamine tablets. Clin Toxicol 1979;14:301-6.
12. [12] Sieniewicz DJ, Nidecker AC. Conglomerate pulmonary disease: a form of talcosis in intravenous methadone abusers. AJR Am J Roentgenol 1980;135:697-702.
13. [13] Farber HW, Falls R, Glauser FL. Transient pulmonary hypertension from the intravenous injection of crushed, suspended pentazocine tablets. Chest 1981;80:178-82.
14. [14] Lamb D, Roberts G. Starch and talc emboli in drug addicts' lungs. J Clin Pathol 1972;25:876-81.
15. [15] Smith WR, Glauser FL, Dearden LC, etal. Deposits of immunoglobulin and complement in the pulmonary tissue of patients with 'heroin lung'. Chest 1978;73:471-6.
16. [16] Shlomi D, Shitrit D, Bendayan D, Sahar G, Shechtman Y, Kramer MR. Successful lung transplantation for talcosis secondary to intravenous abuse of oral drug. Int J Chron Obstruct Pulmon Dis 2008;3:327-30.
17. [17] Johnston WH, Waisman J. Pulmonary corn starch granulomas in a drug user. Light and electron microscopic study of a case. Arch Pathol 1971;92:196-202.
18. [18] Abraham JL, Brambilla C. Particle size for differentiation between inhalation and injection pulmonary talcosis. Environ Res 1980;21:94-6.
19. [19] Arnett EN, Battle WE, Russo JV, Roberts WC. Intravenous injection of talc-containing drugs intended for oral use. A cause of pulmonary granulomatosis and pulmonary hypertension. Am J Med 1976;60:711-18.
20. [20] Marschke G, Haber L, Feinberg M. Pulmonary talc embolization. Chest 1975;68:824-6.
21. [21] Bainborough AR, Jericho KW. Cor pulmonale secondary to talc granulomata in the lungs of a drug addict. Can Med Assoc J 1970;103:1297-8.
22. [22] Robertson CH Jr, Reynolds RC, Wilson JE 3rd. Pulmonary hypertension and foreign body granulomas in intravenous drug abusers. Documentation by cardiac catheterization and lung biopsy. Am J Med 1976;61:657-64.
23. [23] Kringsholm B, Christoffersen P. The nature and the occurrence of birefringent material in different organs in fatal drug addiction. Forensic Sci Int 1987;34:53-62.
24. [24] Carrieri MP, Amass L, Lucas GM, Vlahov D, Wodak A, Woody GE. Buprenorphine use: the international experience. Clin Infect Dis 2006;43 (Suppl 4):S197-215.
25. [25] Roux P, Villes V, Blanche J, etal. Buprenorphine in primary care: risk factors for treatment injection and implications for clinical management. Drug Alcohol Depend 2008;97:105-13.
26. [26] Obadia Y, Perrin V, Feroni I, Vlahov D, Moatti JP. Injecting misuse of buprenorphine among French drug users. Addiction 2001;96:267-72.
27. [27] Brewster D, Humphrey MJ, McLeavy MA. The systemic bioavailability of buprenorphine by various routes of administration. J Pharm Pharmacol 1981;33:500-6.
28. [28] Vidal-Trecan G, Varescon I, Nabet N, Boissonnas A. Intravenous use of prescribed sublingual buprenorphine tablets by drug users receiving maintenance therapy in France. Drug Alcohol Depend 2003;69:175-81.
29. [29] Thiede H, Hagan H, Murrill CS. Methadone treatment and HIV and hepatitis B and C risk reduction among injectors in the Seattle area. J Urban Health 2000;77:331-45.
30. [30] Hahn JA, Page-Shafer K, Lum PJ, etal. Hepatitis C virus seroconversion among young injection drug users: relationships and risks. J Infect Dis 2002;186:1558-64.
31. [31] Scott J. Safety, risks and outcomes for the use of injecting paraphernalia. Bath: University of Bath, Scottish Government Social Research, 2008.
32. [32] McLean S, Bruno R, Brandon S, de Graaff B. Effect of filtration on morphine and particle content of injections prepared from slow-release oral morphine tablets. Harm Reduct J 2009;6:37.
33. [33] Finlinson HA, Colon HM, Negron J, Robles RR. Designing an experimental HIV/HCV intervention to promote the safe re-use of drug preparation materials by injection drug users in Puerto Rico. Harm Reduct J 2008;5:14.